Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer

References

• Emami J, Rezazadeh M, Rostami M, et al. Co-delivery of paclitaxel and α-tocopherol succinate by novel chitosan-based polymeric micelles for improving micellar stability and efficacious combination therapy. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi:10.3109/03639045.2014.935390
   Web of Science ®Google Scholar
• Ouahab A, Shao C, Shen Y, Tu J. Development and characterization of stabilized double loaded mPEG-PDLLA micelles for simultaneous delivery of paclitaxel and docetaxel. Drug Dev Ind Pharm 2014;40:860–8
   PubMed Web of Science ®Google Scholar
• Burris HA, Hanauske AR, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Instit 1992;84:1816–20
   PubMed Web of Science ®Google Scholar
• Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552–7
   PubMed Web of Science ®Google Scholar
• Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011;2011:727241
   PubMedGoogle Scholar
• Dadashzadeh S, Vali A, Rezaie M. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm 2008;353:251–9
   PubMed Web of Science ®Google Scholar
• Chonn A, Semple SC, Cullis PR. Beta 2 glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of “non-self” particles. J Biol Chem 1995;270:25845–9
   PubMed Web of Science ®Google Scholar
• Campbell RB, Fukumura D, Brown EB, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002;62:6831–6
   PubMed Web of Science ®Google Scholar
• Vali AM, Toliyat T, Shafaghi B, Dadashzadeh S. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. Drug Dev Ind Pharm 2008;34:10–23
   PubMed Web of Science ®Google Scholar
• Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer 1994;73:2432–43
   Google Scholar
• Brown RGHGMKS. Emerging therapeutic targets in ovarian cancer. New York (NY): Springer; 2011
   Google Scholar
• Sandip BT, Udupa N, Rao B, Devi P. Thermosensitive liposomes and localised hyperthermia-an effective bimodality approach for tumour management. Ind J Pharmacol 2000;32:214–20
   Google Scholar
• Kono K, Yoshino K, Takagishi T. Effect of poly(ethylene glycol) grafts on temperature-sensitivity of thermosensitive polymer-modified liposomes. J Control Rel 2002;80:321–32
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145–60
   PubMed Web of Science ®Google Scholar
• Lim S-K, Shin DH, Choi M-H, Kim J-S. Enhanced antitumor efficacy of gemcitabine-loaded temperature-sensitive liposome by hyperthermia in tumor-bearing mice. Drug Dev Ind Pharm 2013;40:470–6
   PubMed Web of Science ®Google Scholar
• Jain A, Gulbake A, Jain A, et al. Dual drug delivery using “smart” liposomes for triggered release of anticancer agents. J Nanopart Res 2013;15:1–12
   Web of Science ®Google Scholar
• Sonvico F, Mornet S, Vasseur S, et al. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjugate Chem 2005;16:1181–8
   PubMed Web of Science ®Google Scholar
• Wu J, Liu Q, Lee RJ. A folate receptor-targeted liposomal formulation for paclitaxel. Int J Pharm 2006;316:148–53
   PubMed Web of Science ®Google Scholar
• Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995;1233:134–44
   PubMed Web of Science ®Google Scholar
• Oyewumi MO, Mumper RJ. Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjugate Chem 2002;13:1328–35
   PubMed Web of Science ®Google Scholar
• Weissig V. Liposomes methods and protocols. New York (NY): Humana Press; 2010
   Google Scholar
• Jain A, Gulbake A, Jain A, et al. Development and validation of the HPLC method for simultaneous estimation of paclitaxel and topotecan. J Chromatogr Sci 2014;52:697–703
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2012;64:206–12
   Web of Science ®Google Scholar
• Wang KL, Yang YC, Lai JC, et al. Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model. Drug Dev Ind Pharm 2010;36:1253–8
   PubMed Web of Science ®Google Scholar
• Li H, Lai CS, Wu J, et al. Cytotoxicity, qualitative structure-activity relationship (QSAR), and anti-tumor activity of bismuth dithiocarbamate complexes. J Inorg Biochem 2007;101:809–16
   PubMed Web of Science ®Google Scholar
• Zhang W, Guo Z, Huang D, et al. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide. Biomaterials 2011;32:8555–61
   PubMed Web of Science ®Google Scholar
• Vogt FG, Dell’Orco PC, Diederich AM, et al. A study of variable hydration states in topotecan hydrochloride. J Pharm Biomed Anal 2006;40:1080–8
   PubMed Web of Science ®Google Scholar
• Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG5000–DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 2011;79:276–84
   PubMed Web of Science ®Google Scholar
• Tagami T, Ernsting MJ, Li S-D. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system. J Control Rel 2011;154:290–7
   PubMed Web of Science ®Google Scholar
• Loew C, Riske KA, Lamy MT, Seelig J. Thermal phase behavior of DMPG bilayers in aqueous dispersions as revealed by 2H-and 31P-NMR. Langmuir 2011;27:10041–9
   PubMed Web of Science ®Google Scholar
• Kastantin M, Ananthanarayanan B, Karmali P, et al. Effect of the lipid chain melting transition on the stability of DSPE-PEG (2000) micelles. Langmuir 2009;25:7279–86
   PubMed Web of Science ®Google Scholar
• Sharma A, Bernacki RJ, Straubinger RM, Ojima I. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J Pharm Sci 1995;84:1400–4
   PubMed Web of Science ®Google Scholar
• Yang T, Cui FD, Choi MK, et al. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 2007;338:317–26
   PubMed Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–33
   PubMed Web of Science ®Google Scholar
• van Dam GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011;17:1315–19
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Rel 2010;148:135–46
   PubMed Web of Science ®Google Scholar
• Kono K, Nakashima S, Kokuryo D, et al. Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy. Biomaterials 2011;32:1387–95
   PubMed Web of Science ®Google Scholar
• Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Account Chem Res 2008;41:120–9
   PubMed Web of Science ®Google Scholar
• Sharma M, Malik R, Verma A, et al. Folic acid conjugated guar gum nanoparticles for targeting methotrexate to colon cancer. J Biomed Nanotechnol 2013;9:96–106
   PubMed Web of Science ®Google Scholar
• Peter ME. Programmed cell death: apoptosis meets necrosis. Nature 2011;471:310–12
   PubMed Web of Science ®Google Scholar
• Lin YY, Kao HW, Li JJ, et al. Tumor burden talks in cancer treatment with PEGylated liposomal drugs. PLoS One 2013;8:e63078
   PubMed Web of Science ®Google Scholar
• Singh S, Papareddy P, Morgelin M, et al. Effects of PEGylation on membrane and lipopolysaccharide interactions of host defense peptides. Biomacromolecules 2014;15:1337–45
   PubMed Web of Science ®Google Scholar
• Fetterly GJ, Straubinger RM. Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 2003;5:E32
   PubMedGoogle Scholar
• Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147–62
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004;56:1177–92
   PubMed Web of Science ®Google Scholar
• Gore M, ten Bokkel Huinink W, Carmichael J, et al. Clinical evidence for topotecan-paclitaxel non–cross-resistance in ovarian cancer. J Clin Oncol 2001;19:1893–900
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65:36–48
   PubMed Web of Science ®Google Scholar
• Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J Control Rel 2014;190:531–41
   PubMed Web of Science ®Google Scholar
• Ormrod D, Spencer CM. Topotecan: a review of its efficacy in small cell lung cancer. Drugs 1999;58:533–51
   PubMed Web of Science ®Google Scholar
• Gardner E. Quantitative analytical methods: development and clinical considerations. In: Rudek MA, Chau CH, Figg WD, McLeod HL, eds. Handbook of anticancer pharmacokinetics and pharmacodynamics. Cancer drug discovery and development. New York (NY): Springer; 2014:107–16
   Google Scholar
• Tardi P, Choice E, Masin D, et al. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 2000;60:3389–93
   PubMed Web of Science ®Google Scholar
• van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, et al. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 1995;13:1768–76
   PubMed Web of Science ®Google Scholar
• Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J 2002;367:629–40
   PubMed Web of Science ®Google Scholar
• Lu Y, Ding N, Yang C, et al. Preparation and in vitro evaluation of a folate-linked liposomal curcumin formulation. J Liposome Res 2012;22:110–19
   PubMed Web of Science ®Google Scholar
• Wu L, Tang C, Yin C. Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly (ethylene glycol). Drug Dev Ind Pharm 2010;36:439–48
   PubMed Web of Science ®Google Scholar
• Chen J, Li S, Shen Q, et al. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug Dev Ind Pharm 2011;37:1339–46
   PubMed Web of Science ®Google Scholar